Posterior reversible encephalopathy syndrome (PRES) or reversible posterior leukoencephalopathy syndrome is a syndrome characterized clinically by a wide array of neurological symptoms including headache, confusion, drowsiness, vomiting, seizures and even visual loss in some patients. 1 PRES has been reported in association with adult and pediatric Allo-SCT, as well as adult cord blood transplantation. 2 Typically, PRES occurs in the setting of hypertensive encephalopathy resulting from the use of CY 3 or tacrolimus 4 to prevent the development of GVHD. Herein, we report a case of PRES that occurred in the absence of any exposure to calcineurin inhibitors and was attributable to high-dose steroid administration in a patient undergoing autologous peripheral SCT for multiple myeloma.
A 60-year-old woman with IgG k multiple myeloma characterized by symptomatic bone disease and anemia (Durie-Salmon stage IIIA) presented to the Medical College of Wisconsin for initial evaluation in January 2007. She was initiated on lenalidomide and low-dose dexamethasone, but her treatment was interrupted when she was found on pre-transplant radiographic studies to have a high-grade endometrial carcino-sarcoma requiring surgery and total abdominal irradiation. She was re-started on lenalidomide and dexamethasone post abdominal irradiation, which resulted in an immunofixation-negative CR. The patient was subsequently admitted for autologous PBSCT with melphalan (200 mg/m 2 ) as conditioning therapy in September 2007. She achieved prompt myeloid engraftment with G-CSF administration by day 14-post transplantation. Coincident with myeloid engraftment, the patient developed fever, rash and intractable diarrhea. Colonoscopic examination the same day revealed cecal ulceration and edematous changes in the distal colon. Biopsy confirmed the presence of autologous GVHD occurring in the setting of an engraftment syndrome. 5 The patient was then begun on therapy with high dose steroids (2 mg/kg per day) the following day. Nineteen days post transplantation (4 days after initiation of steroids), the patient developed severe headache and blurring of vision along with a consistently elevated systolic blood pressure over 180 mm Hg and diastolic blood pressure exceeding 110 mm Hg. A magnetic resonance imaging of the brain (Figure 1 ) showed vasogenic edema in the bilateral occipital and posterior parietal lobes consistent with PRES. Discontinuation of steroids and aggressive control of blood pressure led to complete resolution of symptoms within 5 days. Symptoms associated with autologous GVHD also resolved after this brief course of steroids and a single dose of Campath (10 mg). A follow-up brain MRI 3 weeks later showed significant improvement of vasogenic edema (Figure 2) .
Posterior reversible encephalopathy syndrome has been reported to occur in association with numerous co-morbidities, including hypertensive encephalopathy, 6 pre-eclampsia, eclampsia, 7 10 In a large series of patients reported from the Mayo Clinic (Rochester, MN, USA), the most common presenting features were clinical seizures (87%), encephalopathy (92%), visual symptoms (39%) and headache (53%). 2 Radiographically, PRES is characterized by sub-cortical vasogenic edema, patchy symmetrical bilateral involvement with preferential involvement of the posterior brain regions, and in most cases eventual resolution with clinical intervention and reversal of primary insult. 6 By neuro-imaging criteria, fluidattenuated inversion recovery or T2-weighted signal is bright, the diffusion magnetic resonance image is normal and the apparent diffusion coefficient map shows increased activity. The most widely accepted hypothesis regarding the pathogenesis of PRES proposes a capillary leak secondary to drugs that affect the endothelium or increase blood pressure and/or blood vol. 1 It has been suggested that the vertebrobasilar territory, owing to its relatively sparse sympathetic innervation, may experience preferential disruption of autoregulatory mechanisms, leading to increased perfusion and edema. 11 Typically, resolution of symptoms and neuro-imaging abnormalities occur in the range of several days to weeks after removal of the primary inciting agent.
To our knowledge, the occurrence of PRES as a consequence of high-dose steroid administration in SCT patients in the absence of other immunosuppressive medications has not been reported. The consistently elevated systolic blood pressure, the temporal association of steroid therapy with the appearance of neurological symptoms and the eventual resolution with taper of this agent all suggests a steroid-induced hypertensive etiology. This assumes significant clinical importance considering the common use of high-dose steroids in the setting of both autologous and Allo-SCT, particularly for the therapy of GVHD and other inflammatory disorders that can occur in this patient population. Maintaining a high index of clinical suspicion is crucial for prompt recognition of this entity, so that effective therapy can be instituted and permanent neurological damage avoided. 
